CN112294883B - Stomach-strengthening tablet medicinal preparation and preparation method thereof - Google Patents
Stomach-strengthening tablet medicinal preparation and preparation method thereof Download PDFInfo
- Publication number
- CN112294883B CN112294883B CN202011320368.8A CN202011320368A CN112294883B CN 112294883 B CN112294883 B CN 112294883B CN 202011320368 A CN202011320368 A CN 202011320368A CN 112294883 B CN112294883 B CN 112294883B
- Authority
- CN
- China
- Prior art keywords
- weight
- powder
- stomach
- pithecellobium clypearia
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 238000005728 strengthening Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 claims abstract description 33
- 239000003826 tablet Substances 0.000 claims abstract description 24
- 210000002784 stomach Anatomy 0.000 claims abstract description 23
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 20
- 239000007939 sustained release tablet Substances 0.000 claims abstract description 14
- 229940126673 western medicines Drugs 0.000 claims abstract description 13
- 239000000463 material Substances 0.000 claims abstract description 12
- 230000000717 retained effect Effects 0.000 claims abstract description 12
- 229940126680 traditional chinese medicines Drugs 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 41
- 244000033373 Pithecellobium clypearia Species 0.000 claims description 38
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 22
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 22
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 22
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 14
- HWSISDHAHRVNMT-UHFFFAOYSA-N Bismuth subnitrate Chemical compound O[NH+]([O-])O[Bi](O[N+]([O-])=O)O[N+]([O-])=O HWSISDHAHRVNMT-UHFFFAOYSA-N 0.000 claims description 13
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 13
- 229960001482 bismuth subnitrate Drugs 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 239000000395 magnesium oxide Substances 0.000 claims description 13
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 13
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 13
- 238000010298 pulverizing process Methods 0.000 claims description 13
- 239000007962 solid dispersion Substances 0.000 claims description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims description 12
- 239000005720 sucrose Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 241000203383 Schefflera Species 0.000 claims description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 9
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 239000008118 PEG 6000 Substances 0.000 claims description 7
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 7
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 7
- 229960000541 cetyl alcohol Drugs 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920003081 Povidone K 30 Polymers 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 5
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000007950 delayed release tablet Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241000675108 Citrus tangerina Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 abstract description 26
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 abstract description 13
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 abstract description 13
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 abstract description 13
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 abstract description 13
- 229940074391 gallic acid Drugs 0.000 abstract description 13
- 235000004515 gallic acid Nutrition 0.000 abstract description 13
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 abstract description 13
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 abstract description 13
- 229940025878 hesperidin Drugs 0.000 abstract description 13
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000014759 maintenance of location Effects 0.000 abstract description 6
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 229920001477 hydrophilic polymer Polymers 0.000 abstract description 5
- 208000018556 stomach disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 15
- 210000004051 gastric juice Anatomy 0.000 description 10
- 229960004793 sucrose Drugs 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 7
- 241001672694 Citrus reticulata Species 0.000 description 6
- 239000000084 colloidal system Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000220485 Fabaceae Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000203379 Schefflera arboricola Species 0.000 description 1
- 241001136717 Schefflera venulosa Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
Discloses a tablet pharmaceutical preparation for treating gastric diseases, which is a sustained-release tablet retained in the stomach, and the raw materials comprise traditional Chinese medicines and western medicines; and an auxiliary material for forming the sustained-release tablet retained in the stomach. In addition, a preparation method thereof is also disclosed. The medicinal preparation can prolong the retention time of the medicament in the stomach and can continuously and uniformly release the medicament; in addition, the hydrophilic polymer auxiliary materials in the pharmaceutical preparation are beneficial to reducing the drug release difference of the gallic acid and the hesperidin, thereby improving the bioavailability of the gallic acid and the hesperidin.
Description
Technical Field
The invention belongs to the technical field of Chinese and western medicine compound pharmaceutical preparations, and particularly relates to a stomach-strengthening tablet pharmaceutical preparation and a preparation method thereof.
Background
The stomach-strengthening tablet belongs to a special compound preparation of Chinese and Western medicines, comprising Chinese medicines and chemical medicines. The former comprises fructus Pithecellobii Heterophylli, pericarpium Citri Tangerinae, radix aucklandiae, radix Schefflerae Arboricolae and Glycyrrhrizae radix; the latter include bismuth subnitrate, magnesium oxide and aluminum hydroxide. The stomach-strengthening tablet has the main functions of: clearing heat and cooling blood, strengthening spleen and stomach, and relieving hyperacidity and pain; can be used for treating stomach heat burning, abdominal pain, nausea, acid regurgitation, anorexia, listlessness, chronic gastritis, and gastric and duodenal ulcer. The compound preparation is recorded in the seventeenth volume of Chinese medicinal preparations in the standards of the drugs of the ministry of health.
After the compound preparation is orally taken, magnesium oxide and aluminum hydroxide are used for neutralizing gastric acid; part of active ingredients in Glycyrrhrizae radix, pericarpium Citri Tangerinae, and radix aucklandiae act on ulcer surface of stomach wall to protect gastric mucosa; the pithecellobium clypearia and bismuth subnitrate synergically remove helicobacter pylori; the active ingredients in scandent schefflera root have analgesic effect. However, due to the physiological emptying action of the stomach, the compound preparation is quickly brought into the small intestine by the gastric juice, so that the retention time of the compound preparation at the lesion part of the stomach wall is reduced, and the curative effect is greatly influenced.
In addition, the physical properties of the components of the compound preparation, such as the pithecellobium clypearia, the dried orange peel, the costustoot, the scandent schefflera root, the liquorice, and the like, are greatly different. The effective components of the pithecellobium clypearia and the dried orange peel which are used as monarch drugs in the compound preparation are respectively gallic acid and hesperidin, and the solubility of the effective components in an acid solution has large difference, so that the synergistic effect among the drugs of the compound preparation is not facilitated.
The inventor finds that the compound preparation is prepared into a sustained-release drug preparation retained in the stomach, so that the retention time of the drug in the stomach can be prolonged, and the drug can be continuously and uniformly released; in addition, the colloid formed by the hydrophilic polymer auxiliary materials in the medicinal preparation in gastric juice enables the medicaments in the compound preparation to be dispersed in the gastric juice, and is beneficial to reducing the medicament release difference of gallic acid and hesperidin, thereby improving the bioavailability of the gallic acid and the hesperidin.
Disclosure of Invention
In view of the above problems, it is an object of the present invention to provide a positive-gastric-tablet pharmaceutical preparation. The positive gastric tablet preparation is a sustained-release tablet retained in the stomach, and can prolong the retention time of the drug in the stomach and continuously and uniformly release the drug; in addition, the colloid formed by the hydrophilic polymer auxiliary materials in the medicinal preparation in gastric juice enables the medicament in the compound preparation to be dispersed in the gastric juice, which is beneficial to reducing the medicament release difference of the gallic acid and the hesperidin, thereby improving the bioavailability of the gallic acid and the hesperidin.
The second purpose of the invention is to provide a preparation method of the stomach-strengthening tablet pharmaceutical preparation.
In order to achieve the purpose, on one hand, the invention adopts the following technical scheme: the positive-stomach tablet pharmaceutical preparation is characterized in that the positive-stomach tablet pharmaceutical preparation is a sustained-release tablet retained in the stomach, and the raw materials comprise traditional Chinese medicines and western medicines; and an auxiliary material for forming the sustained-release tablet retained in the stomach.
The pharmaceutical preparation according to the present invention is characterized in that the Chinese medicine comprises: 140-240 parts of pithecellobium clypearia; the weight of the tangerine peel, the scandent schefflera root and the liquorice is 14-24 parts respectively; the weight of the costustoot is 6 to 14 parts.
Preferably, the traditional Chinese medicine comprises: the weight of the pithecellobium clypearia is 160-220 parts; the weight of the tangerine peel, the scandent schefflera root and the liquorice is 16 to 22 parts respectively; the weight of the costustoot is 8 to 12 parts.
In a specific embodiment, the Chinese medicine comprises: 187.5 parts of pithecellobium clypearia; the weight of the tangerine peel, the scandent schefflera root and the liquorice is respectively 18.75 parts; the weight of the costustoot is 9.75 parts.
The pharmaceutical preparation is characterized in that the western medicines comprise: 14-24 parts of bismuth subnitrate and magnesium oxide; the weight of the aluminum hydroxide is 24-33 parts.
Preferably, the western medicines include: 16-22 parts of bismuth subnitrate and magnesium oxide respectively; the weight of the aluminum hydroxide is 26-31 parts.
In a specific embodiment, the western medicines include: 18.75 parts of bismuth subnitrate and 18.75 parts of magnesium oxide; the weight of the aluminum hydroxide was 28.5 parts.
The pharmaceutical preparation is characterized in that the auxiliary materials comprise hydroxypropyl methyl cellulose, polyethylene glycol, polyvinylpyrrolidone, cetyl alcohol, sodium bicarbonate, sucrose and magnesium stearate.
The pharmaceutical preparation is characterized in that the weight of the hydroxypropyl methyl cellulose is 240-300 parts; 60-80 parts of polyvinylpyrrolidone; the weight of the hexadecanol is 130-170 parts; 35-45 parts of polyethylene glycol; the weight of the sodium bicarbonate is 35-45 parts; the weight of the sucrose is 16-24 parts; the weight of the magnesium stearate is 4-8 parts.
Preferably, the weight of the hydroxypropyl methyl cellulose is 250-290 parts; 65-75 parts of polyvinylpyrrolidone; the weight of the hexadecanol is 140 to 160 parts; 38-42 parts of polyethylene glycol; 38-42 parts of sodium bicarbonate; the weight of the sucrose is 18-22 parts; the weight of the magnesium stearate is 5-7 parts.
In a specific embodiment, the weight of hydroxypropyl methylcellulose is 268 parts; the weight of the polyvinylpyrrolidone is 70 parts; the weight of the hexadecanol is 150 parts; the weight of the polyethylene glycol is 40 parts; the weight of the sodium bicarbonate is 40 parts; the weight of the cane sugar is 20 parts; the weight of the magnesium stearate is 6 parts.
The pharmaceutical preparation according to the invention is characterized in that the hydroxypropylmethylcellulose is selected from HPMCE50.
The pharmaceutical preparation according to the invention is characterized in that the polyvinylpyrrolidone is selected from PVPK30.
The pharmaceutical preparation according to the invention is characterized in that the polyethylene glycol is selected from PEG 6000.
In another aspect, the present invention provides a method for preparing the above positive gastric tablet pharmaceutical preparation, comprising:
(1) Decocting Pithecellobium clypearia with water, concentrating the decoction, and drying to obtain Pithecellobium clypearia powder;
(2) Obtaining a solid dispersion containing the pithecellobium clypearia and the dried orange peel by a melting method;
(3) Mixing the solid dispersion, western medicines and other traditional Chinese medicines, hydroxypropyl methylcellulose, cetyl alcohol, the rest polyvinylpyrrolidone, sodium bicarbonate, sucrose and magnesium stearate, and tabletting to obtain the sustained-release tablet retained in stomach.
The preparation method is characterized in that the step (2) is specifically as follows: dissolving polyvinylpyrrolidone in small amount of anhydrous ethanol, adding Pithecellobium clypearia powder and pericarpium Citri Tangerinae powder, and stirring; adding the mixture into molten polyethylene glycol, and stirring to uniformly disperse the mixture; solidifying at-20 deg.C, drying, and pulverizing into powder.
The preparation method is characterized in that the sum of the weight of the pithecellobium clypearia powder and the weight of the dried orange peel powder is as follows: weight of polyethylene glycol: weight of polyvinylpyrrolidone =1: (0.9-1.1): (0.9-1.1).
In the invention, the traditional Chinese medicine materials all meet the relevant national standard or local medicinal material standard. Wherein the Pithecellobium clypearia is dried leaf of Pithecellobium clypearia of Leguminosae; radix aucklandiae is dried root of radix aucklandiae of Compositae; schefflera arboricola is dry whole plant of schefflera venulosa (Schw.) harms of Araliaceae; the pericarpium Citri Tangerinae is dried pericarp of Citrus reticulata Blanco of Rutaceae; the Glycyrrhrizae radix is dried root of Glycyrrhrizae radix of Leguminosae.
In the invention, the western medicines all accord with the related medicine standards of Chinese pharmacopoeia.
Advantageously, in the above-mentioned method for producing a tablet for positive stomach, the case involving pulverization is preferably pulverized into a powder of 100 to 150 mesh.
Advantageously, the hardness is controlled to be 3-4kg during tabletting.
In a specific embodiment, there is provided a specific preparation method of the above-mentioned positive-stomach tablet pharmaceutical preparation, comprising:
(1) Decocting Pithecellobium clypearia with water for 2 times, and adding 8-12 times of water each time; concentrating the decoction under reduced pressure to obtain fluid extract with relative density of 1.4, drying under reduced pressure, and pulverizing into 100-150 mesh Pithecellobium clypearia powder;
(2) Respectively pulverizing pericarpium Citri Tangerinae, radix aucklandiae, radix Schefflerae Arboricolae, glycyrrhrizae radix, bismuth subnitrate, magnesium oxide and aluminum hydroxide into 100-150 mesh powder;
(3) Dissolving polyvinylpyrrolidone in small amount of anhydrous ethanol, adding Pithecellobium clypearia powder and pericarpium Citri Tangerinae powder, stirring, adding into molten polyethylene glycol, and stirring to disperse uniformly; solidifying in a refrigerator at-20 deg.C, drying, and pulverizing into 100-150 mesh powder to obtain solid dispersion containing Pithecellobium clypearia and pericarpium Citri Tangerinae; wherein the sum of the weight of the pithecellobium clypearia powder and the weight of the dried orange peel powder is as follows: weight of polyethylene glycol: weight of polyvinylpyrrolidone =1: (0.9-1.1): (0.9-1.1);
(4) Mixing the solid dispersion, western medicines, the rest traditional Chinese medicines, hydroxypropyl methylcellulose, cetyl alcohol, the rest polyvinylpyrrolidone, sodium bicarbonate, sucrose and magnesium stearate uniformly, sieving with a 100-150 mesh sieve, and directly performing dry tabletting with hardness controlled at 3-4kg to obtain the gastric retention sustained release tablet.
Compared with the prior art, the medicinal preparation can prolong the detention time of the medicament in the stomach and can continuously and uniformly release the medicament; in addition, the colloid formed by the hydrophilic polymer auxiliary materials in the medicinal preparation in gastric juice enables the medicament in the compound preparation to be dispersed in the gastric juice, which is beneficial to reducing the medicament release difference of the gallic acid and the hesperidin, thereby improving the bioavailability of the gallic acid and the hesperidin.
Without wishing to be bound by any theory, the solid dispersion comprising pithecellobium clypearia and dried orange peel and the further formed gastro-retentive sustained release tablet of the present invention play a key role in achieving the above technical effects.
Detailed Description
The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how the compounds, compositions, articles, devices, and/or methods described and claimed herein are made and evaluated, and are intended to be purely exemplary and are not intended to limit the scope of what the inventors regard as their invention. Efforts have been made to ensure accuracy with respect to numbers (e.g., amounts, temperature, etc.) but some errors and deviations should be accounted for.
Unless otherwise indicated, parts are parts by weight, temperatures are in degrees celsius or at ambient temperature, and pressures are at or near atmospheric. There are many variations and combinations of reaction conditions (e.g., component concentrations, desired solvents, solvent mixtures, temperatures, pressures, and other reaction ranges) and conditions that can be used to optimize the purity and yield of the product obtained by the process. Only reasonable routine experimentation will be required to optimize such process conditions.
Example 1
Raw materials:
the weight of the pithecellobium clypearia is 187.5g; the weight of the tangerine peel, the scandent schefflera root and the liquorice is respectively 18.75g; the weight of the costustoot is 9.75g; the weights of bismuth subnitrate and magnesium oxide are respectively 18.75g; the weight of the aluminum hydroxide is 28.5g; the weight of HPMCE50 is 268g; the weight of the polyvinylpyrrolidone PVPK30 is 70g; the weight of the hexadecanol is 150g; the weight of the polyethylene glycol PEG6000 is 40g; the weight of the sodium bicarbonate is 40g; the weight of the sucrose is 20g; the weight of magnesium stearate was 6g.
The preparation method comprises the following steps:
(1) Decocting Pithecellobium clypearia with water for 2 times, and adding 10 times of water each time; the decoction was concentrated under reduced pressure at 70 ℃ and 0.1MPa to a fluid extract with a relative density of 1.4, followed by drying under reduced pressure and pulverizing to 120 mesh powder of Pithecellobium clypearia, and the weight was 23.8g.
(2) Respectively pulverizing pericarpium Citri Tangerinae, radix aucklandiae, radix Schefflerae Arboricolae and Glycyrrhrizae radix, bismuth subnitrate, magnesium oxide and aluminum hydroxide into 120 mesh powder.
(3) Dissolving 40 parts of polyvinylpyrrolidone (PVPK) 30 in a small amount of anhydrous ethanol, adding pithecellobium clypearia powder and dried orange peel powder, stirring uniformly, adding the pithecellobium clypearia powder and dried orange peel powder into 40 parts of molten polyethylene glycol (PEG 6000), and stirring to disperse uniformly; solidifying in a refrigerator at-20 deg.C, drying, and pulverizing into 120 mesh powder to obtain solid dispersion containing Pithecellobium clypearia and pericarpium Citri Tangerinae.
(4) Mixing the solid dispersion, western medicines and other traditional Chinese medicines, hydroxypropyl methylcellulose HPMCE50, cetyl alcohol, the rest polyvinylpyrrolidone PVPK30, sodium bicarbonate, sucrose and magnesium stearate, sieving with 120 mesh sieve, directly performing dry tabletting with hardness of 3-4kg, and making into 1000 tablets to obtain the delayed release tablet retained in stomach.
Comparative example 1
Weighing polyvinylpyrrolidone PVP K30, polyethylene glycol PEG6000, pithecellobium clypearia powder and dried orange peel powder according to the corresponding proportion of the solid dispersion in the step (3) in the embodiment 1, and grinding to uniformly mix the powder; the other steps and conditions were the same as in example 1 to obtain a sustained-release tablet retained in the stomach.
Comparative example 2
Raw materials:
the weight of the pithecellobium clypearia is 750g; the weight of the tangerine peel, the scandent schefflera root and the liquorice is 75g respectively; the weight of the costustoot is 39g; the weight of bismuth subnitrate and the weight of magnesium oxide are respectively 75g; the weight of the aluminum hydroxide is 114g; 118g of cane sugar; 7.5g of glycoprotein; silica gel micropowder 1.5g.
The preparation method comprises the following steps:
(1) Decocting Pithecellobium clypearia with water for 2 times, and adding 10 times of water each time; the decoction was concentrated under reduced pressure at 70 ℃ and 0.1MPa to a clear paste with a relative density of 1.4, then dried under reduced pressure and pulverized into 120 mesh monkey ear ring powder, weighing 95.4g.
(2) Respectively pulverizing pericarpium Citri Tangerinae, radix aucklandiae, radix Schefflerae Arboricolae and Glycyrrhrizae radix, bismuth subnitrate, magnesium oxide and aluminum hydroxide into 120 mesh powder.
(3) Mixing the above extract powder, western medicine, other Chinese medicinal materials, aspartame, sucrose and silica gel micropowder uniformly, sieving with 120 mesh sieve, directly tabletting by dry method, controlling hardness at 3-4kg, and making into 1000 tablets to obtain common tablet.
In vitro floating performance
The gastro-retentive sustained release tablets of example 1 and comparative example 1 were placed in a 0.1M hydrochloric acid solution, and the rise time (min), duration (h) and appearance during floating were measured.
The results are shown in Table 1.
TABLE 1
| Rising drift time (min) | Duration (h) | Appearance during floating | |
| Example 1 | 1.8 | 12 | Complete without cracking |
| Comparative example 1 | 5.7 | 11 | Partial cleavage |
In vitro Release Properties
According to the relevant regulations of Chinese pharmacopoeia 2015 year edition, the tablets of example 1 and comparative examples 1-2 are placed in a rotating basket of 300ml artificial gastric juice, samples are taken according to the specified time, and after filtration by using a 0.8 mu m microporous filter membrane, the subsequent filtrate is taken; then, the content of gallic acid and hesperidin in the zhengwei tablets was measured by the HPLC method of Tang De Zhi "(national folk medicine of China, 2016, 02, 25, 3 rd edition, pages 12-13) to prepare a control solution and a test solution, and the cumulative release rates (%) of gallic acid and hesperidin in example 1 and comparative examples 1-2 at different times were measured according to their chromatographic conditions.
The results are shown in Table 2.
TABLE 2
The results show that, compared with comparative examples 1-2, the pharmaceutical formulation of example 1 of the present invention can not only prolong the retention time of the drug in the stomach but also continuously and uniformly release the drug; in addition, the colloid formed by the hydrophilic polymer auxiliary materials in the medicinal preparation in gastric juice enables the medicaments in the compound preparation to be dispersed in the gastric juice, and is beneficial to reducing the medicament release difference of gallic acid and hesperidin, thereby improving the bioavailability of the gallic acid and the hesperidin.
Without wishing to be bound by any theory, the solid dispersion comprising pithecellobium clypearia and dried orange peel and the further formed gastro-retentive sustained release tablet of the present invention play a key role in achieving the above technical effects.
It should be understood that the detailed description of the invention is intended to illustrate the spirit and principles of the invention, and is not intended to limit the scope of the invention. Furthermore, it should be understood that various changes, substitutions, deletions, modifications or adjustments may be made by those skilled in the art after reading the disclosure of the present invention, and such equivalents are also within the scope of the invention as defined in the appended claims.
Claims (2)
1. The positive-stomach tablet pharmaceutical preparation is characterized in that the positive-stomach tablet pharmaceutical preparation is a sustained-release tablet retained in the stomach, and the raw materials comprise traditional Chinese medicines and western medicines; and, an adjuvant for forming a gastro-retentive, sustained release tablet;
the traditional Chinese medicine comprises the following components: the weight of the pithecellobium clypearia is 187.5g; the weight of the tangerine peel, the scandent schefflera root and the liquorice is respectively 18.75g; the weight of the costustoot is 9.75g;
the western medicine comprises the following components: the weights of bismuth subnitrate and magnesium oxide are respectively 18.75g; the weight of the aluminum hydroxide is 28.5g;
the auxiliary materials consist of hydroxypropyl methyl cellulose, polyethylene glycol, polyvinylpyrrolidone, cetyl alcohol, sodium bicarbonate, sucrose and magnesium stearate; wherein the weight of the hydroxypropyl methyl cellulose is 268g; the weight of the polyvinylpyrrolidone is 70g; the weight of the hexadecanol is 150g; the weight of the polyethylene glycol is 40g; the weight of the sodium bicarbonate is 40g; the weight of the sucrose is 20g; the weight of magnesium stearate is 6g;
the hydroxypropyl methylcellulose is selected from HPMC E50; the polyvinylpyrrolidone is selected from PVP K30; the polyethylene glycol is selected from PEG 6000;
the preparation method of the stomach-strengthening tablet pharmaceutical preparation comprises the following steps:
(1) Decocting Pithecellobium clypearia with water for 2 times, and adding 10 times of water each time; concentrating the decoction at 70 deg.C under 0.1MPa vacuum degree to obtain fluid extract with relative density of 1.4, drying under reduced pressure, pulverizing into 120 mesh powder, and weighing 23.8g;
(2) Respectively crushing dried orange peel, costustoot, scandent schefflera root and liquorice, bismuth subnitrate, magnesium oxide and aluminum hydroxide into 120-mesh powder;
(3) Adding 40 parts of polyvinylpyrrolidone PVP K30 into a small amount of absolute ethyl alcohol for dissolving, adding pithecellobium clypearia powder and dried orange peel powder, stirring uniformly, adding the pithecellobium clypearia powder and dried orange peel powder into 40 parts of molten polyethylene glycol PEG6000, and stirring to disperse uniformly; solidifying in a refrigerator at-20 deg.C, drying, and pulverizing into 120 mesh powder to obtain solid dispersion containing Pithecellobium clypearia and pericarpium Citri Tangerinae;
(4) Mixing the solid dispersion, western medicines and other traditional Chinese medicines, hydroxypropyl methylcellulose HPMC E50, cetyl alcohol, the rest polyvinylpyrrolidone PVP K30, sodium bicarbonate, sucrose and magnesium stearate, sieving with 120 mesh sieve, directly dry-tabletting, and making into 1000 tablets with hardness of 3-4kg to obtain the sustained-release tablet retained in stomach.
2. A method for preparing the positive gastric tablet pharmaceutical formulation of claim 1, comprising:
(1) Decocting Pithecellobium clypearia with water for 2 times, and adding 10 times of water each time; concentrating the decoction at 70 deg.C under 0.1MPa vacuum degree to obtain fluid extract with relative density of 1.4, drying under reduced pressure, pulverizing into 120 mesh powder, and weighing 23.8g;
(2) Respectively crushing dried orange peel, costustoot, scandent schefflera root and liquorice, bismuth subnitrate, magnesium oxide and aluminum hydroxide into 120-mesh powder;
(3) Adding 40 parts of polyvinylpyrrolidone PVP K30 into a small amount of absolute ethyl alcohol for dissolving, adding pithecellobium clypearia powder and dried orange peel powder, stirring uniformly, adding the pithecellobium clypearia powder and dried orange peel powder into 40 parts of molten polyethylene glycol PEG6000, and stirring to disperse uniformly; solidifying in a refrigerator at-20 deg.C, drying, and pulverizing into 120 mesh powder to obtain solid dispersion containing Pithecellobium clypearia and pericarpium Citri Tangerinae;
(4) Mixing the solid dispersion, western medicines and other traditional Chinese medicines, hydroxypropyl methylcellulose HPMC E50, cetyl alcohol, the rest polyvinylpyrrolidone PVP K30, sodium bicarbonate, sucrose and magnesium stearate, sieving with 120 mesh sieve, directly performing dry tabletting with hardness of 3-4kg, and making into 1000 tablets to obtain the delayed release tablet retained in stomach.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011320368.8A CN112294883B (en) | 2020-11-23 | 2020-11-23 | Stomach-strengthening tablet medicinal preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011320368.8A CN112294883B (en) | 2020-11-23 | 2020-11-23 | Stomach-strengthening tablet medicinal preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112294883A CN112294883A (en) | 2021-02-02 |
| CN112294883B true CN112294883B (en) | 2023-04-14 |
Family
ID=74335118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011320368.8A Active CN112294883B (en) | 2020-11-23 | 2020-11-23 | Stomach-strengthening tablet medicinal preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112294883B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115531485A (en) * | 2022-10-26 | 2022-12-30 | 陕西中医药大学 | Pharmaceutical composition for treating chronic gastritis and preparation method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1080168A (en) * | 1992-06-19 | 1994-01-05 | 丛繁滋 | The preparation method of the Entogastric lingering slow releasing preparation of treatment digestive ulcer medicament |
| CN102349876B (en) * | 2011-10-21 | 2016-09-07 | 江西省药明扬海医药科技有限公司 | A kind of treat gastric ulcer and the medicine of duodenal ulcer and compound method thereof |
| CN105616626A (en) * | 2014-10-31 | 2016-06-01 | 康普药业股份有限公司 | Pharmaceutical preparation for treating gastric disease and preparation method of pharmaceutical preparation |
-
2020
- 2020-11-23 CN CN202011320368.8A patent/CN112294883B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112294883A (en) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1210095B1 (en) | Withania somnifera composition | |
| CN113082166A (en) | Method for preparing health food from herba Dendrobii | |
| CN112294883B (en) | Stomach-strengthening tablet medicinal preparation and preparation method thereof | |
| TWI513478B (en) | Lopamine hydrochloride (LOPERAMIDE) hydrochloride film preparation | |
| CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| WO2008136636A1 (en) | Composition for fast disintegrating tablet containing herbal extract and its preparation method | |
| JP2019516706A (en) | Novel crystalline form of dapagliflozin and method for producing and use thereof | |
| KR102095536B1 (en) | Oral formulation for improved dissolution rate and disintegrability of herbal extract | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CA2492156C (en) | Tablet composition containing kampo medicinal extract and its manufacturing process | |
| CN100450504C (en) | Medication for treating pharyngitis | |
| CN107854671A (en) | A Na series anaesthetic intragastric floating sustained-release preparations and preparation method thereof | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN101269123A (en) | Secondary development novel technique for thirst eliminating capsule for lowering blood sugar | |
| CN113861261B (en) | Hainan holly leaf triterpenoid sapogenin extract, extraction process, preparation and application | |
| CN102772455A (en) | Seabuckthorn flavone dispersible tablets | |
| CN111166847B (en) | Pharmaceutical composition containing turmeric, tablet thereof and preparation method | |
| CN115531493B (en) | Compound preparation and preparation method thereof | |
| CN113599361B (en) | Ginkgo terpene lactone dripping pill and its preparing method | |
| CN101011383A (en) | Dispersible tablet of coumarin derivative and its preparation method | |
| CN100525747C (en) | Process for preparing Tibetan medicine soup promoting medicine composition | |
| CN103735591A (en) | Composition for treating digestive ulcer and applications thereof | |
| CN1322851C (en) | Tripterygium total terpenoids drop pill and its preparation method | |
| CN1327829C (en) | Sustained release preparation of root of indian stringbush | |
| CN105748959B (en) | Pharmaceutical composition for reducing blood pressure, preparation containing pharmaceutical composition and application of pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |